AstraZeneca, Daiichi’s Enhertu snags ultrafast approval in broad HER2-low breast Cancer Use
A new era of HER2-low treatment is upon us.
Thanks to a landmark FDA approval Friday, AstraZeneca and Daiichi Sankyo’s Enhertu has become the first therapy targeted to treat unresectable or metastatic breast cancer expressing low levels of HER2, a brand-new category that was once part of the HER2-negative group.
